TISIDB

Summary
Symbol	FABP4
Name	fatty acid binding protein 4, adipocyte
Aliases	A-FABP; AFABP; ALBP; HEL-S-104; adipocyte lipid-binding protein; adipocyte-type fatty acid-binding protein; ......
Chromosomal Location	8q21.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm. Nucleus. Note=Depending on the nature of the ligand, a conformation change exposes a nuclear localization motif and the protein is transported into the nucleus. Subject to constitutive nuclear export (By similarity).
Domain	PF00061 Lipocalin / cytosolic fatty-acid binding protein family
Function	Lipid transport protein in adipocytes. Binds both long chain fatty acids and retinoic acid. Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0001933 negative regulation of protein phosphorylation GO:0006469 negative regulation of protein kinase activity GO:0006638 neutral lipid metabolic process GO:0006639 acylglycerol metabolic process GO:0006641 triglyceride metabolic process GO:0010035 response to inorganic substance GO:0010038 response to metal ion GO:0010226 response to lithium ion GO:0016042 lipid catabolic process GO:0019433 triglyceride catabolic process GO:0031349 positive regulation of defense response GO:0032103 positive regulation of response to external stimulus GO:0033673 negative regulation of kinase activity GO:0042326 negative regulation of phosphorylation GO:0042632 cholesterol homeostasis GO:0044242 cellular lipid catabolic process GO:0045444 fat cell differentiation GO:0046461 neutral lipid catabolic process GO:0046464 acylglycerol catabolic process GO:0046486 glycerolipid metabolic process GO:0046503 glycerolipid catabolic process GO:0050727 regulation of inflammatory response GO:0050729 positive regulation of inflammatory response GO:0050872 white fat cell differentiation GO:0050873 brown fat cell differentiation GO:0051348 negative regulation of transferase activity GO:0055088 lipid homeostasis GO:0055092 sterol homeostasis GO:0071241 cellular response to inorganic substance GO:0071248 cellular response to metal ion GO:0071285 cellular response to lithium ion
Molecular Function	GO:0005504 fatty acid binding GO:0031406 carboxylic acid binding GO:0033293 monocarboxylic acid binding GO:0043168 anion binding
Cellular Component	GO:0005811 lipid particle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03320 PPAR signaling pathway
Reactome	R-HSA-1266738: Developmental Biology R-HSA-163560: Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis R-HSA-73923: Lipid digestion, mobilization, and transport R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-381340: Transcriptional regulation of white adipocyte differentiation

Summary
Symbol	FABP4
Name	fatty acid binding protein 4, adipocyte
Aliases	A-FABP; AFABP; ALBP; HEL-S-104; adipocyte lipid-binding protein; adipocyte-type fatty acid-binding protein; ......
Chromosomal Location	8q21.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FABP4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between FABP4 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
29437708	Breast Carcinoma	Inhibit immunity (T cell function)	Although upregulation of A-FABP was inversely associated with breast cancer survival, deficiency of A-FABP significantly reduced mammary tumor growth and metastasis. Furthermore, the protumor effect of A-FABP was mediated by TAM, in particular, in a subset of TAM with a CD11b+F4/80+MHCII-Ly6C- phenotype. A-FABP expression in TAM facilitated protumor IL6/STAT3 signaling through regulation of the NFκB/miR-29b pathway.

Summary
Symbol	FABP4
Name	fatty acid binding protein 4, adipocyte
Aliases	A-FABP; AFABP; ALBP; HEL-S-104; adipocyte lipid-binding protein; adipocyte-type fatty acid-binding protein; ......
Chromosomal Location	8q21.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FABP4 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FABP4
Name	fatty acid binding protein 4, adipocyte
Aliases	A-FABP; AFABP; ALBP; HEL-S-104; adipocyte lipid-binding protein; adipocyte-type fatty acid-binding protein; ......
Chromosomal Location	8q21.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FABP4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-1.114	0.274
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.743	0.438
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.619	0.671
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.542	0.605
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.917	0.604
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	2.381	0.236
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.145	0.86
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.72	0.63
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-1.041	0.505
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.013	0.996
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.636	0.595
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.638	0.0936

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FABP4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	FABP4
Name	fatty acid binding protein 4, adipocyte
Aliases	A-FABP; AFABP; ALBP; HEL-S-104; adipocyte lipid-binding protein; adipocyte-type fatty acid-binding protein; ......
Chromosomal Location	8q21.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FABP4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FABP4
Name	fatty acid binding protein 4, adipocyte
Aliases	A-FABP; AFABP; ALBP; HEL-S-104; adipocyte lipid-binding protein; adipocyte-type fatty acid-binding protein; ......
Chromosomal Location	8q21.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FABP4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FABP4. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FABP4
Name	fatty acid binding protein 4, adipocyte
Aliases	A-FABP; AFABP; ALBP; HEL-S-104; adipocyte lipid-binding protein; adipocyte-type fatty acid-binding protein; ......
Chromosomal Location	8q21.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FABP4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FABP4
Name	fatty acid binding protein 4, adipocyte
Aliases	A-FABP; AFABP; ALBP; HEL-S-104; adipocyte lipid-binding protein; adipocyte-type fatty acid-binding protein; ......
Chromosomal Location	8q21.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FABP4 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FABP4
Name	fatty acid binding protein 4, adipocyte
Aliases	A-FABP; AFABP; ALBP; HEL-S-104; adipocyte lipid-binding protein; adipocyte-type fatty acid-binding protein; ......
Chromosomal Location	8q21.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FABP4 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FABP4
Name	fatty acid binding protein 4, adipocyte
Aliases	A-FABP; AFABP; ALBP; HEL-S-104; adipocyte lipid-binding protein; adipocyte-type fatty acid-binding protein; ......
Chromosomal Location	8q21.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FABP4 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse FABP4